These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 34092112)

  • 1. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
    Mayer IA; Zhao F; Arteaga CL; Symmans WF; Park BH; Burnette BL; Tevaarwerk AJ; Garcia SF; Smith KL; Makower DF; Block M; Morley KA; Jani CR; Mescher C; Dewani SJ; Tawfik B; Flaum LE; Mayer EL; Sikov WM; Rodler ET; Wagner LI; DeMichele AM; Sparano JA; Wolff AC; Miller KD
    J Clin Oncol; 2021 Aug; 39(23):2539-2551. PubMed ID: 34092112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
    Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ;
    J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
    Smith KL; Zhao F; Mayer IA; Tevaarwerk AJ; Garcia SF; Arteaga CL; Symmans WF; Park BH; Burnette BL; Makower DF; Block M; Morley KA; Jani CR; Mescher C; Dewani SJ; Brown-Glaberman U; Flaum LE; Mayer EL; Sikov WM; Rodler ET; DeMichele AM; Sparano JA; Wolff AC; Miller KD; Wagner LI
    Cancer; 2024 May; 130(10):1747-1757. PubMed ID: 38236702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
    Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
    Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
    Schneider BP; Jiang G; Ballinger TJ; Shen F; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Hancock BA; Kassem N; Helft P; O'Neil B; Storniolo AMV; Badve S; Miller KD; Radovich M
    J Clin Oncol; 2022 Feb; 40(4):345-355. PubMed ID: 34910554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-based chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
    Taşçı EŞ; Kutlu Y; Ölmez ÖF; Mutlu AU; Gündoğdu Y; Seyyar M; Şahin E; Çabuk D; Majidova N; Uğurlu İ; Demirci A; Aydın D; Çavdar E; Bayram S; Yıldırım N; Karataş F; Eryılmaz MK; Çağlayan D; Menekşe S; Kut E; Arak H; Keser M; Sunar V; Perkin P; Şakalar T; Oyan B; Sönmez Ö; Özer L; Yıldız İ
    Expert Opin Pharmacother; 2024 Mar; 25(4):477-484. PubMed ID: 38568074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
    Asleh K; Lluch A; Goytain A; Barrios C; Wang XQ; Torrecillas L; Gao D; Ruiz-Borrego M; Leung S; Bines J; Guerrero-Zotano Á; García-Sáenz JÁ; Cejalvo JM; Herranz J; Torres R; Haba-Rodriguez J; Ayala F; Gómez H; Rojo F; Nielsen TO; Martin M
    Clin Cancer Res; 2023 Jan; 29(2):389-400. PubMed ID: 36346687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
    Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
    J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
    Gluz O; Nitz U; Kolberg-Liedtke C; Prat A; Christgen M; Kuemmel S; Mohammadian MP; Gebauer D; Kates R; Paré L; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Wuerstlein R; Graeser M; Pelz E; Jóźwiak K; Zu Eulenburg C; Kreipe HH; Harbeck N;
    Clin Cancer Res; 2022 Nov; 28(22):4995-5003. PubMed ID: 35797219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
    Bell R; Brown J; Parmar M; Toi M; Suter T; Steger GG; Pivot X; Mackey J; Jackisch C; Dent R; Hall P; Xu N; Morales L; Provencher L; Hegg R; Vanlemmens L; Kirsch A; Schneeweiss A; Masuda N; Overkamp F; Cameron D
    Ann Oncol; 2017 Apr; 28(4):754-760. PubMed ID: 27993816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
    Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
    JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
    Beyerlin K; Jimenez R; Zangardi M; Fell GG; Edmonds C; Johnson A; Bossuyt V; Specht M; Mulvey TM; Moy B; Ellisen LW; Isakoff SJ; Bardia A; Spring LM
    J Oncol Pharm Pract; 2021 Dec; 27(8):1883-1890. PubMed ID: 33153384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
    JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer.
    Pereira MFI; Buzatto IPC; Carrara HHA; Buono FO; de Andrade JM; Orlandini LF; Tiezzi DG
    Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 39176205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
    Tolaney SM; DeMichele A; Takano T; Rugo HS; Perou C; Lynce F; Parsons HA; Santa-Maria CA; Rocque GB; Yao W; Sun SW; Mocci S; Partridge AH; Carey LA
    Future Oncol; 2024; 20(31):2343-2355. PubMed ID: 38922307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.